EP2477611A1 — (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
Assigned to Sanofi Aventis Deutschland GmbH · Expires 2012-07-25 · 14y expired
What this patent protects
The invention relates to solid pharmaceutical compositions comprising (Z)-2- cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune dis…
USPTO Abstract
The invention relates to solid pharmaceutical compositions comprising (Z)-2- cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.
Drugs covered by this patent
- Aubagio (TERIFLUNOMIDE) · Sanofi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.